AI Article Synopsis
- The c-fms proto-oncogene, also known as M-CSFR or CSF-1R, is found on various malignant tumor cells and myeloid cells, and was found to be overexpressed in adult T-cell leukemia/lymphoma (ATLL).
- In the study, M-CSFR signaling was linked to the growth of lymphoma cells, and inhibiting M-CSFR led to increased cell death (apoptosis) in these lymphoma cells.
- The ATL-T cell line produced M-CSF and IL-34, ligands for M-CSFR, which were also co-expressed in most ATLL cases, suggesting that targeting M-CSFR could serve as a promising therapeutic strategy for ATLL through
Article Abstract
The c-fms proto-oncogene is also known as macrophage colony stimulating factor receptor (M-CSFR) or colony-stimulating factor-1 receptor (CSF-1R), and is expressed on several types of malignant tumor cells and myeloid cells. In the present study, we found that overexpression of M-CSFR was present in adult T-cell leukemia/lymphoma (ATLL) cases. M-CSFR signaling was associated with lymphoma cell proliferation, and M-CSFR inhibition induced apoptosis in lymphoma cells. The ATLL cell line ATL-T expressed M-CSF/CSF-1 and interleukin (IL)-34, which are both M-CSFR ligands. M-CSF and IL-34 expression was seen in ATLL cases, and co-expression of these ligands was detected in 11 of 13 ATLL cases. M-CSFR inhibition suppressed programmed death-1 and -2 ligand in ATL-T cells and macrophages stimulated with conditioned medium from ATL-T cells. Thus, an M-CSFR inhibitor may be useful as additional therapy against ATLL due to direct and indirect mechanisms.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407477 | PMC |
| http://dx.doi.org/10.3960/jslrt.18034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low Survival Due to Higher Risk of Relapse and Nonrelapse Mortality After Allogeneic HSCT in ATL Compared with AML and ALL.
Transplant Cell Ther
January 2025
Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
Background: Patients with adult T-cell leukemia/lymphoma (ATL) are considered to have worse outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) than patients with other hematological malignancies, owing to high risk of relapse and immunocompromised status. However, no studies have compared transplant outcomes between patients with ATL and those with other hematological malignancies using a large-scale database.
Objectives: To compare transplant outcomes between patients with ATL and those with other leukemias and to identify factors contributing to worse transplant outcomes in ATL patients.
Targeted antibody therapy as a treatment strategy for aggressive adult T-cell leukemia/lymphoma.
Leuk Res
January 2025
Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Sakuragaoka 8-35-1, Kagoshima, Japan. Electronic address:
The standard treatment for aggressive adult T-cell leukemia/lymphoma (ATL) is multi-agent chemotherapy, but the use of more intense cytotoxic anticancer agents is becoming more difficult with the aging of patients at the time of diagnosis. As a means of overcoming this hurdle, antibody drugs, which are supposed to be less toxic, have been developed for ATL. The advent of the anti-CC chemokine receptor 4 (CCR4) antibody mogamulizumab has significantly advanced ATL treatment.
View Article and Find Full Text PDFPrognosis of aggressive adult T-cell leukemia/lymphoma with central nervous system infiltration and utility of CD7 versus CADM1 flowcytometric plots of cerebrospinal fluid.
Ann Hematol
January 2025
Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
The prognosis of adult T-cell leukemia/lymphoma (ATL) with primary central nervous system (CNS) involvement has been unclear since the advent of new therapies. Recently, we have shown that flow cytometric CD7/CADM1 analysis of CD4 + cells (HAS-Flow) is useful to detect ATL cells that are not morphologically diagnosed as ATL cells. We investigated the role of CNS involvement in ATL using cytology and HAS-Flow by analyzing cerebrospinal fluid (CSF) from 73 aggressive ATL cases.
View Article and Find Full Text PDFIntegrative analysis of ATAC-seq and RNA-seq for cells infected by human T-cell leukemia virus type 1.
PLoS Comput Biol
January 2025
Department of Hematology, Rheumatology and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy (HAM) after a long latent period in a fraction of infected individuals. These HTLV-1-infected cells typically have phenotypes similar to that of CD4+T cells, but the cell status is not well understood. To extract the inherent information of HTLV-1-infected CD4+ cells, we integratively analyzed the ATAC-seq and RNA-seq data of the infected cells.
View Article and Find Full Text PDFDeclining trend of HTLV-1 among organ/ tissue donors in Iranian Tissue Bank between 2014-2021.
Retrovirology
December 2024
Iranian Tissue Bank and Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- HTLV-1 is linked to serious health issues like Adult T-cell Leukemia/Lymphoma and HAM/TSP; thus, screening potential organ donors for the virus is vital due to high transmission risks, particularly in kidney transplant recipients.
- A study at the Iranian Tissue Bank from 2014 to 2021 found that 3% of 3,814 potential organ/tissue donors tested positive for HTLV-1, with rates significantly dropping from 6% to 0.5% over the years.
- Females showed a higher positivity rate (4%) than males (2%), and donors with brain death had a much lower infection rate (0.2%) compared to those with circulatory death (4%).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!